Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma;Radiothérapie stéréotaxique et radiothérapie interne sélective du carcinome hépatocellulaire.

Cancer/Radiotherapie

Volumn 15, Issue 1, 2011, Pages 54-63

  Bujold, A ^a   Dawson, L A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Hepatocellular carcinoma; Radioembolization; Selective internal radiation therapy; Stereotactic radiation therapy

Indexed keywords

IODINE 131; RHENIUM 188; YTTRIUM 90;

AORTA DISSECTION; ARTIFICIAL EMBOLISM; ASCITES; BRAIN DISEASE; BREATH HOLDING; DIGESTIVE SYSTEM ULCER; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMOBILIZATION; LIVER CELL CARCINOMA; LIVER PARENCHYMA; LIVER TOXICITY; LYMPHOCYTOPENIA; NAUSEA; OVERALL SURVIVAL; PATIENT SELECTION; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; POST RADIOEMBOLIZATION SYNDROME; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIATION SICKNESS; RADIOEMBOLIZATION; SHORT SURVEY; STEREOTACTIC TREATMENT; TREATMENT PLANNING; TUMOR VOLUME; UPPER ABDOMINAL PAIN;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER; LIVER NEOPLASMS; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 79551571698     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2010.11.003     Document Type: Short Survey

References (78)

1. Ben-Josef E., Normolle D., Ensminger W.D., Walker S., Tatro D., Ten Haken R.K., et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005, 23:8739-8747.
2. Park H.C., Seong J., Han K.H., Chon C.Y., Moon Y.M., Suh C.O. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002, 54:150-155.
3. Pan C.C., Kavanagh B.D., Dawson L.A., Li X.A., Das S.K., Miften M., et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010, 76:S94-S100.
4. Park C., Papiez L., Zhang S., Story M., Timmerman R.D. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:847-852.
5. Sawrie S.M., Fiveash J.B., Caudell J.J. Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity. Cancer Control 2010, 17:111-119.
6. De Bari B., Pointreau Y., Rio E., Mirabel X., Mornex F. Normal tissue tolerance to external beam radiation therapy: liver. Cancer Radiother 2010, 14:344-349.
7. Quivrin M., Mornex F., Enachescu C., Martin E., Ligey-Bartolomeu A., Nouhaud E., et al. Primary tumours of the liver. Cancer Radiother 2010, 14:S103-S110.
8. Hashimoto T., Tokuuye K., Fukumitsu N., Igaki H., Hata M., Kagei K., et al. Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006, 65:196-202.
9. Mitsunaga S., Kinoshita T., Kawashima M., Konishi M., Nakagohri T., Takahashi S., et al. Extrahepatic portal vein occlusion without recurrence after pancreaticoduodenectomy and intraoperative radiation therapy. Int J Radiat Oncol Biol Phys 2006, 64:730-735.
10. Raoul J.L., Boucher E., Rolland Y., Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 2010, 7:41-49.
11. Riaz A., Lewandowski R.J., Kulik L.M., Mulcahy M.F., Sato K.T., Ryu R.K., et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009, 20:1121-1130. [quiz 31].
12. Kennedy A.S., McNeillie P., Dezarn W.A., Nutting C., Sangro B., Wertman D., et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009, 74:1494-1500.
13. Wolfort R.M., Papillion P.W., Turnage R.H., Lillien D.L., Ramaswamy M.R., Zibari G.B. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size. AFP level, and histologic grade. Int Surg 2010, 95:67-75.
14. Wang M.H., Ji Y., Zeng Z.C., Tang Z.Y., Fan J., Zhou J., et al. Impact factors for micro-invasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume. Int J Radiat Oncol Biol Phys 2010, 76:467-476.
15. Case R.B., Moseley D.J., Sonke J.J., Eccles C.L., Dinniwell R.E., Kim J., et al. Interfraction and intrafraction changes in amplitude of breathing motion in stereotactic liver radiotherapy. Int J Radiat Oncol Biol Phys 2010, 77:918-925.
16. Kubas A., Chapet O., Merle P., d'Hombres A., Lorchel F., d'Hombres H., et al. Impact dosimétrique du blocage respiratoire dans le traitement du carcinome hépatocellulaire par irradiation de conformation. Cancer Radiother 2009, 13:24-29.
17. Dawson L.A., Eccles C., Bissonnette J.P., Brock K.K. Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int J Radiat Oncol Biol Phys 2005, 62:1247-1252.
18. Eccles C., Brock K.K., Bissonnette J.P., Hawkins M., Dawson L.A. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. Int J Radiat Oncol Biol Phys 2006, 64:751-759.
19. Lax I., Blomgren H., Naslund I., Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994, 33:677-683.
20. Linthout N., Bral S., Van de Vondel I., Verellen D., Tournel K., Gevaert T., et al. Treatment delivery time optimization of respiratory gated radiation therapy by application of audio-visual feedback. Radiother Oncol 2009, 91:330-335.
21. Shin Y.J., Kim M.S., Yoo S.Y., Cho C.K., Seo Y.S., Kang J.K., et al. Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies. Tumori 2010, 96:65-70.
22. Fuss M., Salter B.J., Cavanaugh S.X., Fuss C., Sadeghi A., Fuller C.D., et al. Daily ultrasound-based image-guided targeting for radiotherapy of upper abdominal malignancies. Int J Radiat Oncol Biol Phys 2004, 59:1245-1256.
23. Sonke J.J., Zijp L., Remeijer P., van Herk M. Respiratory correlated cone beam CT. Med Phys 2005, 32:1176-1186.
24. Brock K.K. Results of a multi-institution deformable registration accuracy study (MIDRAS). Int J Radiat Oncol Biol Phys 2010, 76:583-596.
25. Kitamura K., Shirato H., Shimizu S., Shinohara N., Harabayashi T., Shimizu T., et al. Registration accuracy and possible migration of internal fiducial gold marker implanted in prostate and liver treated with real-time tumor-tracking radiation therapy (RTRT). Radiother Oncol 2002, 62:275-281.
26. Choi B.O., Choi I.B., Jang H.S., Kang Y.N., Jang J.S., Bae S.H., et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 2008, 8:351.
27. Kirilova A., Lockwood G., Choi P., Bana N., Haider M.A., Brock K.K., et al. Three-dimensional motion of liver tumors using cine-magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2008, 71:1189-1195.
28. Wu D.H., Liu L., Chen L.H. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2004, 10:2184-2189.
29. Liu R., Buatti J.M., Howes T.L., Dill J., Modrick J.M., Meeks S.L. Optimal number of beams for stereotactic body radiotherapy of lung and liver lesions. Int J Radiat Oncol Biol Phys 2006, 66:906-912.
30. Yang Z.X., Wang D., Wang G., Zhang Q.H., Liu J.M., Peng P., et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010, 136:625-630.
31. de Pooter J.A., Wunderink W., Mendez Romero A., Storchi P.R.M., Heijmen B.J.M. PTV dose prescription strategies for SBRT of metastatic liver tumours. Radiother Oncol 2007, 85:260-266.
32. Fuss M., Shi C., Papanikolaou N. Tomotherapeutic stereotactic body radiation therapy: techniques and comparison between modalities. Acta Oncol 2006, 45:953-960.
33. Eccles C.L., Bissonnette J.P., Craig T., Taremi M., Wu X., Dawson L.A. Treatment planning study to determine potential benefit of intensity-modulated radiotherapy versus conformal radiotherapy for unresectable hepatic malignancies. Int J Radiat Oncol Biol Phys 2008, 72:582-588.
34. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
35. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60.
36. Blomgren H. Radiosurgery for tumors in the body: clinical experience using a new method. J Radiosurg 1998, 1:63-74.
37. Blomgren H., Lax I., Naslund I., Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first 31 patients. Acta Oncol 1995, 34:861-870.
38. Choi B.O., Jang H.S., Kang K.M., Lee S.W., Kang Y.N., Chai G.Y., et al. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol 2006, 36:154-158.
39. Son S.H., Choi B.O., Ryu M.R., Kang Y.N., Jang J.S., Bae S.H., et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys 2010, 78:1073-1080.
40. Wulf J., Guckenberger M., Haedinger U., Oppitz U., Mueller G., Baier K., et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 2006, 45:838-847.
41. Taguchi H., Sakuhara Y., Hige S., Kitamura K., Osaka Y., Abo D., et al. Intercepting radiotherapy using a real-time tumor-tracking radiotherapy system for highly selected patients with hepatocellular carcinoma unresectable with other modalities. Int J Radiat Oncol Biol Phys 2007, 69:376-380.
42. Sandroussi C., Dawson L.A., Lee M., Guindi M., Fischer S., Ghanekar A., et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 2010, 23:299-306.
43. Mendez Romero A., Wunderink W., Hussain S.M., De Pooter J.A., Heijmen B.J.M., Nowak P.C.J.M., et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 2006, 45:831-837.
44. Mendez Romero A., Wunderink W., van Os R.M., Nowak P.J., Heijmen B.J., Nuyttens J.J., et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys 2008, 70:1447-1452.
45. Tse R.V., Hawkins M., Lockwood G., Kim J.J., Cummings B., Knox J., et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008, 26:657-664. [Erratum appears in J Clin Oncol 2008;26:3911-2].
46. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
47. Cardenes H.R., Price T.R., Perkins S.M., Maluccio M., Kwo P., Breen T.E., et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010, 12:218-225.
48. Hoffe S.E., Finkelstein S.E., Russell M.S., Shridhar R. Non surgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Control 2010, 17:100-110.
49. Takeda A., Takahashi M., Kunieda E., Takeda T., Sanuki N., Koike Y., et al. Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: preliminary results for efficacy and toxicity. Hepatol Res 2008, 38:60-69.
50. Ariel I.M. Treatment of Inoperable Primary Pancreatic and Liver Cancer by the Intra-Arterial Administration of Radioactive Isotopes (Y90 Radiating Microspheres). Ann Surg 1965, 162:267-278.
51. Salem R., Lewandowski R.J., Atassi B., Gordon S.C., Gates V.L., Barakat O., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005, 16:1627-1639.
52. Sangro B., Bilbao J.I., Boan J., Martinez-Cuesta A., Benito A., Rodriguez J., et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006, 66:792-800.
53. Salem R., Thurston K.G. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006, 17:1251-1278.
54. 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 1991, 20:953-963.
55. Raoul J.L., Guyader D., Bretagne J.F., Duvauferrier R., Bourguet P., Bekhechi D., et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994, 35:1782-1787.
56. 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995, 76:2202-2210.
57. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997, 26:1156-1161.
58. Lau W.Y., Lai E.C.H., Leung T.W.T., Yu S.C.H. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008, 247:43-48.
59. Lau W.Y., Leung T.W., Ho S.K., Chan M., Machin D., Lau J., et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999, 353:797-801.
60. Brans B., Van Laere K., Gemmel F., Defreyne L., Vanlangenhove P., Troisi R., et al. Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2002, 29:928-932.
61. Bernal P., Raoul J.L., Vidmar G., Sereegotov E., Sundram F.X., Kumar A., et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys 2007, 69:1448-1455.
62. Salem R., Lewandowski R.J., Mulcahy M.F., Riaz A., Ryu R.K., Ibrahim S., et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138:52-64.
63. Sohn J.H., Choi H.J., Lee J.T., Lee J.D., Kim J.H., Moon Y.M., et al. Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. Oncology 2009, 76:1-9.
64. Leung W.T., Lau W.Y., Ho S., Chan M., Leung N., Lin J., et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994, 35:1313-1318.
65. Raoul J.I., Bretagne J.F., Caucanas J.P., Pariente E.A., Boyer J., Paris J.C., et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol. Cancer 1992, 69:346-352.
66. 131I lipiodol therapy for unresectable hepatocellular carcinoma. Aust N Z J Surg 2002, 72:210-214.
67. 131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006, 65:435-444.
68. Kulik L.M., Carr B.I., Mulcahy M.F., Lewandowski R.J., Atassi B., Ryu R.K., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008, 47:71-81.
69. Woodall C.E., Scoggins C.R., Ellis S.F., Tatum C.M., Hahl M.J., Ravindra K.V., et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis?. J Am Coll Surg 2009, 208:375-382.
70. 166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res 2006, 12:543-548.
71. Marelli L., Shusang V., Buscombe J.R., Cholongitas E., Stigliano R., Davies N., et al. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med 2009, 50:871-877.
72. Partensky C., Sassolas G., Henry L., Paliard P., Maddern G.J. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 2000, 135:1298-1300.
73. 131I-labelled lipiodol. Br J Surg 2003, 90:1379-1383.
74. Riaz A., Kulik L., Lewandowski R.J., Ryu R.K., Giakoumis Spear G., Mulcahy M.F., et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009, 49:1185-1193.
75. Ferenci P., Lockwood A., Mullen K., Tarter R., Weissenborn K., Blei A.T. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35:716-721.
76. Lee M.T., Kim J.J., Dinniwell R., Brierley J., Lockwood G., Wong R., et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009, 27:1585-1591.
77. Lim L., Gibbs P., Yip D., Shapiro J.D., Dowling R., Smith D., et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 2005, 35:222-227.
78. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000, 31:840-845. The cancer of the liver Italian Program (CLIP) Investigators.